Recently, researchers have characterized the biological significance of gene fusions as a potential molecular targeted therapy owing to their high specificity and selectivity towards the cancer cell.
Global TRK Inhibitors Market, Drug Sales & Clinical Trials Insight 2026 Report Analysis & Data Highlights:
- Research Methodology
- Global & Regional Market Analysis
- Global TRK Inhibitors Market Opportunity Assessment: > USD 2 Billion
- Market & Drug Sales Insight 2020 Till 2026
- Approved Drug In Market: 2 Drugs (Vitrakvi & Rozlytrek)
- Approved TRK Drug Patent, Price & Sales insight 2020 Till 2026
- Future Market Assessment By Indication Till 2026
- Ongoing Clinical Trials Assessment by Status, Phase & Region
- Key Market Dynamics
- Competitor Landscape
Download Report:
https://www.kuickresearch.com/report-trk-inhibitors-market-size-sales-growth-forecast
Recently, researchers have characterized the biological significance of gene fusions as a potential molecular targeted therapy owing to their high specificity and selectivity towards the cancer cell. Studies have demonstrated that NTRK gene fusions involving NTRK1, NTRK2, or NTRK3 (encoding the neurotrophin receptors TRKA, TRKB, and TRKC, respectively) are oncogenic drivers of various adult and pediatric tumor types. They can occur in more than 80% of certain rare cancers, such as infantile fibrosarcoma and in less than 1% of common cancer types, such as lung cancer. To target these fusions, scientists have developed tropomyosin receptor kinase (TRK) inhibitors as an alternative for the treatment for the cancer.
At present, two TRK inhibitors, larotrectinib (Vitrakvi) and entrectinib (Rozlytrek), have been approved by the FDA for treating patients with solid tumors that have an NTRK fusion without a known acquired drug-resistant mutation. The introduction of novel TRK inhibitors in the global market have shown to significantly enhance the overall survival rate in NTRK positive solid tumors. The results from the phase-III study of the TRK inhibitor Vitrakvi in patients with NTRK positive solid tumor has shown long-term efficacy of the agent, including in those with central nervous system (CNS) metastases. In addition, the drug also increased the overall survival rate and progression free survival rate among patients when compared with conventional cancer therapies, thus boosting this segment.
Apart from approved TRK inhibitors, there are currently more than 100 ongoing clinical trials which are evaluating the novel TRK inhibitors as monotherapy or combinational therapy in the management of cancer. Repotrectinib develop by Turning Point Therapeutics is a next generation ROS1/TRK TKI that binds inside ATP pockets in the presence of mutations. The results from phase-I/II trial have shown encouraging response in overcoming the resistance to first generation TRK inhibitor. In addition, Loxo Oncology has also developed next generation TRK inhibitor, LOXO-195 which has also shown to overcome resistance and enhance survival rates in cancer patients. The promising pipeline and the large number of ongoing clinical trial suggest the promising future of TRK inhibitor in global cancer therapeutics market.
The global TRK inhibitor market is highly competitive and has adopted strategic alliances to maintain their position in market. For instance in 2021, AUM Bioscience entered into a strategic collaboration agreement with Handok and CMG Pharmaceuticals or the worldwide (ex-Korea) development, manufacturing and commercialization rights of a highly specific, safe and efficacious CHC-2014, Pan-TRK inhibitor. CHC2014 is completing a Phase I in Korea and has shown promising data to justify advancement to a tumor agnostic registration program. Further in 2022, AUM Bioscience and Asychem agreed to collaborate on the process development, and the clinical and commercial production, of AUM 601, which is a highly selective oral small molecule inhibitor of the tropomyosin receptor kinase (TRK) for treating rare cancers. The other players in the market include AstraZeneca, Pfizer, Bayer, Loxo Oncology, Innocare, and Ono Pharmaceutical.
As per our report analysis, the global TRK inhibitor market is expected to surpass US$ 2 Billion by 2026. Certain factors that are driving the market growth include increasing prevalence of cancer and growing research and development activities. Apart from this, the increase in awareness about the availability of drugs, upcoming new drugs approval, and rise in government initiatives will also boost the growth of market. The report provides insights into the patent, price, dosage and sales analysis of the currently approved TRK inhibitors. On the basis of indication, the market is segment into lung, colorectal, breast, glioblastoma and papillary thyroid cancer. Keeping in mind the various driver and challenges, the future outlook of TRK inhibitors has also been analyzed in the report.
Contact:
Neeraj Chawla
Research Head
Kuick Research
+91-9810410366